Arrowhead Pharmaceuticals Faces Pivotal Week with Key FDA Decision and Earnings Report
Published on 11/17/2025 at 06:56 | Redaktion boerse-global.de
Investor attention is firmly fixed on Arrowhead Pharmaceuticals this week as the biotechnology firm approaches two significant milestones that could dramatically influence its trajectory. With the stock having surged more than 85% since the start of the year, the market is questioning whether this momentum can be sustained or if the company is poised for a setback.
Before the market opens on November 25, Arrowhead is scheduled to release its full-year financial results. Market experts are projecting earnings of $0.13 per share for the most recent quarter. A critical point of analysis will be the company’s cash position. Management has previously indicated that its existing liquid assets are sufficient to fund Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
